The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has ...

Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers ...

GSK (GSK) stock is in focus as bepirovirsen hepatitis B therapy developed with Ionis Pharmaceuticals (IONS) undergoes FDA ...

Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The Trump ...

The World Health Organization (WHO) released a new report on hepatitis today, marking the World Hepatitis Summit. Since 2015, ...

About 90% of infants infected at birth go on to develop chronic infection ...

The US FDA has granted priority review to GSK's bepirovirsen, an antisense oligonucleotide therapy for chronic hepatitis B licensed from Ionis Pharmaceuticals. Supported by positive Phase 3 trial ...

The decision by the Center for Disease Control and Prevention to stop recommending giving infants a dose of the hepatitis B ...

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the ...

New studies warn delaying the hepatitis B birth dose could leave more babies vulnerable to infection and long-term illness.